Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents.

Griebel G, Stemmelin J, Lopez-Grancha M, Boulay D, Boquet G, Slowinski F, Pichat P, Beeské S, Tanaka S, Mori A, Fujimura M, Eguchi J.

Sci Rep. 2019 Dec 2;9(1):18045. doi: 10.1038/s41598-019-54557-5.

2.

The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents.

Griebel G, Stemmelin J, Lopez-Grancha M, Fauchey V, Slowinski F, Pichat P, Dargazanli G, Abouabdellah A, Cohen C, Bergis OE.

Sci Rep. 2018 Feb 5;8(1):2416. doi: 10.1038/s41598-018-20895-z.

3.

Creativity in large pharmaceutical research organizations: unleash the hungry drug hunter.

Griebel G.

Br J Pharmacol. 2017 Jul;174(13):2152-2153. doi: 10.1111/bph.13775. Epub 2017 Apr 3. No abstract available.

4.

The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia.

Griebel G, Pichat P, Boulay D, Naimoli V, Potestio L, Featherstone R, Sahni S, Defex H, Desvignes C, Slowinski F, Vigé X, Bergis OE, Sher R, Kosley R, Kongsamut S, Black MD, Varty GB.

Sci Rep. 2016 Oct 13;6:35320. doi: 10.1038/srep35320.

5.
6.
7.

Pharmacology, Biochemistry and Behavior: the 2015 transition.

Koob GF, Griebel G.

Pharmacol Biochem Behav. 2015 Apr;131:iii. doi: 10.1016/j.pbb.2015.02.001. Epub 2015 Feb 4. No abstract available.

PMID:
25661528
8.

Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents.

Griebel G, Pichat P, Beeské S, Leroy T, Redon N, Jacquet A, Françon D, Bert L, Even L, Lopez-Grancha M, Tolstykh T, Sun F, Yu Q, Brittain S, Arlt H, He T, Zhang B, Wiederschain D, Bertrand T, Houtmann J, Rak A, Vallée F, Michot N, Augé F, Menet V, Bergis OE, George P, Avenet P, Mikol V, Didier M, Escoubet J.

Sci Rep. 2015 Jan 6;5:7642. doi: 10.1038/srep07642.

9.

The CRF₁ receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: comparison with paroxetine and d-cycloserine.

Philbert J, Beeské S, Belzung C, Griebel G.

Behav Brain Res. 2015 Feb 15;279:41-6. doi: 10.1016/j.bbr.2014.11.006. Epub 2014 Nov 12.

PMID:
25446760
10.

Mice deficient in cryptochrome 1 (cry1 (-/-)) exhibit resistance to obesity induced by a high-fat diet.

Griebel G, Ravinet-Trillou C, Beeské S, Avenet P, Pichat P.

Front Endocrinol (Lausanne). 2014 Apr 9;5:49. doi: 10.3389/fendo.2014.00049. eCollection 2014.

11.

Optogenetics to study the circuits of fear- and depression-like behaviors: a critical analysis.

Belzung C, Turiault M, Griebel G.

Pharmacol Biochem Behav. 2014 Jul;122:144-57. doi: 10.1016/j.pbb.2014.04.002. Epub 2014 Apr 13. Review.

PMID:
24727401
12.

CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents.

Douma TN, Millan MJ, Boulay D, Griebel G, Verdouw PM, Westphal KG, Olivier B, Groenink L.

Psychopharmacology (Berl). 2014 Apr;231(7):1289-303. doi: 10.1007/s00213-013-3315-2. Epub 2013 Nov 2.

PMID:
24186076
13.

Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.

Gao Z, Hurst WJ, Czechtizky W, Francon D, Griebel G, Nagorny R, Pichat P, Schwink L, Stengelin S, Hendrix JA, George PG.

Bioorg Med Chem Lett. 2013 Nov 15;23(22):6141-5. doi: 10.1016/j.bmcl.2013.09.006. Epub 2013 Sep 8.

PMID:
24076172
14.

50 years of hurdles and hope in anxiolytic drug discovery.

Griebel G, Holmes A.

Nat Rev Drug Discov. 2013 Sep;12(9):667-87. doi: 10.1038/nrd4075. Review.

15.

Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia?

Boulay D, Ho-Van S, Bergis O, Avenet P, Griebel G.

Behav Pharmacol. 2013 Oct;24(7):543-51. doi: 10.1097/FBP.0b013e3283654044.

PMID:
23928693
16.

The CRF₁ receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: comparison with paroxetine and D-cycloserine.

Philbert J, Belzung C, Griebel G.

Psychopharmacology (Berl). 2013 Jul;228(1):97-107. doi: 10.1007/s00213-013-3020-1. Epub 2013 Feb 14.

PMID:
23407783
17.

Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543.

Dournes C, Beeské S, Belzung C, Griebel G.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:213-20.

PMID:
23367508
18.

Further evidence for the sleep-promoting effects of 5-HT₂A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats.

Griebel G, Beeské S, Jacquet A, Laufrais C, Alonso R, Decobert M, Avenet P, Françon D.

Neuropharmacology. 2013 Jul;70:19-26. doi: 10.1016/j.neuropharm.2012.12.008. Epub 2013 Jan 12.

PMID:
23321054
19.
20.

The CRF₁ receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the hypothalamic pituitary adrenal axis.

Philbert J, Pichat P, Palme R, Belzung C, Griebel G.

Pharmacol Biochem Behav. 2012 Sep;102(3):415-22. doi: 10.1016/j.pbb.2012.05.013. Epub 2012 May 31.

PMID:
22659580
21.

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Griebel G, Holsboer F.

Nat Rev Drug Discov. 2012 May 18;11(6):462-78. doi: 10.1038/nrd3702. Review.

PMID:
22596253
22.

Awakening properties of newly discovered highly selective H₃ receptor antagonists in rats.

Griebel G, Decobert M, Jacquet A, Beeské S.

Behav Brain Res. 2012 Jul 1;232(2):416-20. doi: 10.1016/j.bbr.2012.04.033. Epub 2012 Apr 26.

PMID:
22561131
23.

SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents.

Griebel G, Pichat P, Pruniaux MP, Beeské S, Lopez-Grancha M, Genet E, Terranova JP, Castro A, Sánchez JA, Black M, Varty GB, Weiner I, Arad M, Barak S, De Levie A, Guillot E.

Pharmacol Biochem Behav. 2012 Aug;102(2):203-14. doi: 10.1016/j.pbb.2012.04.004. Epub 2012 Apr 21.

PMID:
22542742
24.

Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?

Griebel G, Beeské S.

Pharmacol Ther. 2012 Jan;133(1):116-23. doi: 10.1016/j.pharmthera.2011.09.007. Epub 2011 Sep 22. Review.

PMID:
21963368
25.

Antidepressants recruit new neurons to improve stress response regulation.

Surget A, Tanti A, Leonardo ED, Laugeray A, Rainer Q, Touma C, Palme R, Griebel G, Ibarguen-Vargas Y, Hen R, Belzung C.

Mol Psychiatry. 2011 Dec;16(12):1177-88. doi: 10.1038/mp.2011.48. Epub 2011 May 3.

26.

Acute inescapable stress exposure induces long-term sleep disturbances and avoidance behavior: a mouse model of post-traumatic stress disorder (PTSD).

Philbert J, Pichat P, Beeské S, Decobert M, Belzung C, Griebel G.

Behav Brain Res. 2011 Aug 1;221(1):149-54. doi: 10.1016/j.bbr.2011.02.039. Epub 2011 Mar 4.

PMID:
21377492
27.

The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice.

Urani A, Philbert J, Cohen C, Griebel G.

Pharmacol Biochem Behav. 2011 May;98(3):425-31. doi: 10.1016/j.pbb.2011.02.019. Epub 2011 Feb 26.

PMID:
21356230
28.

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Black MD, Stevens RJ, Rogacki N, Featherstone RE, Senyah Y, Giardino O, Borowsky B, Stemmelin J, Cohen C, Pichat P, Arad M, Barak S, De Levie A, Weiner I, Griebel G, Varty GB.

Psychopharmacology (Berl). 2011 May;215(1):149-63. doi: 10.1007/s00213-010-2124-0. Epub 2010 Dec 22.

PMID:
21181124
29.

The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition.

Rogacki N, Lopez-Grancha M, Naimoli V, Potestio L, Stevens RJ, Pichat P, Bergis OE, Cohen C, Varty GB, Griebel G.

Pharmacol Biochem Behav. 2011 May;98(3):405-11. doi: 10.1016/j.pbb.2010.11.017. Epub 2010 Nov 27.

PMID:
21115031
30.

Risk assessment as an evolved threat detection and analysis process.

Blanchard DC, Griebel G, Pobbe R, Blanchard RJ.

Neurosci Biobehav Rev. 2011 Mar;35(4):991-8. doi: 10.1016/j.neubiorev.2010.10.016. Epub 2010 Nov 5. Review.

PMID:
21056591
31.

SSR181507, a dopamine D₂ receptor and 5-HT(₁A) receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities.

Boulay D, Depoortere R, Louis C, Lacave M, Lucas MT, Griebel G.

Pharmacol Biochem Behav. 2011 Jan;97(3):428-35. doi: 10.1016/j.pbb.2010.09.019.

PMID:
20920519
32.

Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery.

Borelli KG, Defensor EB, Blanchard DC, Blanchard RJ, Griebel G.

Neurosci Lett. 2010 Nov 26;485(3):241-5. doi: 10.1016/j.neulet.2010.09.021. Epub 2010 Sep 19.

PMID:
20849917
33.

Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression.

Overstreet DH, Naimoli VM, Griebel G.

Pharmacol Biochem Behav. 2010 Aug;96(2):206-10. doi: 10.1016/j.pbb.2010.05.006. Epub 2010 May 12.

PMID:
20470817
34.

The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.

Boulay D, Bergis O, Avenet P, Griebel G.

Neuropsychopharmacology. 2010 Jan;35(2):416-27. doi: 10.1038/npp.2009.144.

35.

Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress.

Stemmelin J, Cohen C, Yalcin I, Keane P, Griebel G.

Behav Brain Res. 2010 Jan 20;206(2):310-2. doi: 10.1016/j.bbr.2009.09.003. Epub 2009 Sep 8.

PMID:
19744528
36.

Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.

Barak S, Arad M, De Levie A, Black MD, Griebel G, Weiner I.

Neuropsychopharmacology. 2009 Jun;34(7):1753-63. doi: 10.1038/npp.2008.232. Epub 2009 Jan 21.

37.

Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.

Black MD, Varty GB, Arad M, Barak S, De Levie A, Boulay D, Pichat P, Griebel G, Weiner I.

Psychopharmacology (Berl). 2009 Jan;202(1-3):385-96. doi: 10.1007/s00213-008-1289-2. Epub 2008 Aug 16.

PMID:
18709358
38.

Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.

Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C, Cohen C, Alonso R, Vigé X, Biton B, Steinberg R, Sevrin M, Oury-Donat F, George P, Bergis O, Griebel G, Avenet P, Scatton B.

Pharmacol Biochem Behav. 2008 Nov;91(1):47-58. doi: 10.1016/j.pbb.2008.06.009. Epub 2008 Jun 24.

PMID:
18621075
39.

Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal.

Surget A, Wang Y, Leman S, Ibarguen-Vargas Y, Edgar N, Griebel G, Belzung C, Sibille E.

Neuropsychopharmacology. 2009 May;34(6):1363-80. doi: 10.1038/npp.2008.76. Epub 2008 Jun 4.

40.

Defensive responses to predator threat in the rat and mouse.

Blanchard DC, Blanchard RJ, Griebel G.

Curr Protoc Neurosci. 2005 Feb;Chapter 8:Unit 8.19. doi: 10.1002/0471142301.ns0819s30.

PMID:
18428625
41.

Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal.

Surget A, Saxe M, Leman S, Ibarguen-Vargas Y, Chalon S, Griebel G, Hen R, Belzung C.

Biol Psychiatry. 2008 Aug 15;64(4):293-301. doi: 10.1016/j.biopsych.2008.02.022. Epub 2008 Apr 11.

PMID:
18406399
42.

Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression.

Overstreet DH, Stemmelin J, Griebel G.

Pharmacol Biochem Behav. 2008 Jun;89(4):623-6. doi: 10.1016/j.pbb.2008.02.020. Epub 2008 Feb 26.

PMID:
18358519
43.

Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models.

Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G.

Pharmacol Biochem Behav. 2008 Mar;89(1):36-45. Epub 2007 Nov 5.

PMID:
18045668
44.

Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling.

Kodas E, Cohen C, Louis C, Griebel G.

Psychopharmacology (Berl). 2007 Oct;194(2):161-71. Epub 2007 Jun 8.

PMID:
17557151
45.

Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.

Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G.

Neuropsychopharmacology. 2008 Feb;33(3):574-87. Epub 2007 Apr 25.

46.

SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile.

Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, Godet D, Lanneau C, Santamaria R, Chesney F, Léonardon J, Granger P, Debono MW, Bohme GA, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Vigé X, Voltz C, Rouquier L, Souilhac J, Santucci V, Gueudet C, Françon D, Steinberg R, Griebel G, Oury-Donat F, George P, Avenet P, Scatton B.

Neuropsychopharmacology. 2007 Jan;32(1):1-16. Epub 2006 Oct 4.

47.

SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.

Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B.

Neuropsychopharmacology. 2007 Jan;32(1):17-34. Epub 2006 Aug 23.

48.

Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats.

Salomé N, Stemmelin J, Cohen C, Griebel G.

Psychopharmacology (Berl). 2006 Aug;187(2):237-44. Epub 2006 Jun 2.

PMID:
16779555
49.

Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils.

Salomé N, Stemmelin J, Cohen C, Griebel G.

Pharmacol Biochem Behav. 2006 Apr;83(4):533-9. Epub 2006 Apr 19.

PMID:
16624395
50.

Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders.

Belzung C, Yalcin I, Griebel G, Surget A, Leman S.

CNS Neurol Disord Drug Targets. 2006 Apr;5(2):135-45. Review.

PMID:
16611088

Supplemental Content

Loading ...
Support Center